Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL99181 | 0.85 | ALDH1A1 (0.59) | CYP2C19ALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL1443816 | 0.85 | MAOA (0.53) | CYP2C19NPC1RAB9ASLC6A4SLC6A3 | |
| SCHEMBL3910619 | 0.84 | ALDH1A1 (0.57) | NPC1RAB9ASLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL5213661 | 0.84 | ALDH1A1 (0.56) | CYP2C19NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL21522574 | 0.84 | ALDH1A1 (0.52) | CYP2C19NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL13960511 | 0.83 | HDAC1 (0.51) | CYP2C19NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL31500633 | 0.83 | HSP90AA1 (0.57) | CYP2C19NPC1RAB9ASLC6A4SLC6A3 | |
| SCHEMBL5214121 | 0.83 | HSP90AA1 (0.57) | CYP2C19NPC1RAB9ASLC6A4SLC6A3 | |
| SCHEMBL5213400 | 0.82 | ALDH1A1 (0.59) | NPC1RAB9ASLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL13235760 | 0.82 | TACR1 (0.57) | CYP2C19RAB9AALDH1A1NTRK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7555415-B2 | Methods for the design of estrogen receptor ligands | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| US-7378427-B2 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378427-B2 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378427-B2 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH (US) | 2008-05-27 | — | — | US | disclosed |
| US-7304073-B2 | Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors | WYETH (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1856151-A2 | ESTROGEN RECEPTOR STRUCTURE | Wyeth (US) | 2007-11-21 | — | — | EP | disclosed |
| EP-1567502-B1 | SUBSTITUTED DIHYDROPHENANTHRIDINESUL FONAMIDES | WYETH CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1758866-A1 | PROCESSES FOR PREPARING 6-ALKYL-5-ARYLSULFONYL- DIHYDROPHENANTHRIDINES | Wyeth (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006078733-A2 | ESTROGEN RECEPTOR STRUCTURE | WYETH (US) | 2006-07-27 | — | — | WO | disclosed |
| US-20060160836-A1 | Estrogen receptor structure | WYETH | 2006-07-20 | — | — | US | disclosed |
| US-20060025436-A1 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | WYETH (US) | 2006-02-02 | — | — | US | disclosed |
| WO-2006009831-A1 | PROCESSES FOR PREPARING 6-ALKYL-5-ARYLSULFONYL- DIHYDROPHENANTHRIDINES | WYETH (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20050119276-A1 | Methods of treating inflammatory bowel disease using NF-kB inhibitors | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050119324-A1 | Methods of treating atherosclerosis using NF-kB inhibitors | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050113405-A1 | Methods of treating rheumatoid arthritis using NF-kB inhibitors | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| US-6894061-B2 | Substituted dihydrophenanthridinesulfonamides | WYETH (US) | 2005-05-17 | — | — | US | disclosed |
| WO-2005039581-A1 | USE OF ESTROGEN RECEPTOR LIGANDS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039583-A1 | METHOD OF TREATING RHEUMATOID ARTHRITIS USING NF-kB INHIBITORS | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
| WO-2005039582-A1 | METHODS OF TREATING ATHEROSCLEROSIS USING NF-kB INHIBITORS | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113405-A1 | Methods of treating rheumatoid arthritis using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | CYP2C19 4005/4885NPC1 4646/4885RAB9A 4071/4885 |
| US-20050119324-A1 | Methods of treating atherosclerosis using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | CYP2C19 3669/4885NPC1 2070/4885RAB9A 4731/4885 |
| US-20060025436-A1 | Processes for preparing 6-alkyl-5-arylsulfonyl-dihydrophenanthridines | QDPR, RPS9, RPS4Y1 | CYP2C19 171/4885NPC1 4494/4885RAB9A 99/4885 |
| US-20050119276-A1 | Methods of treating inflammatory bowel disease using NF-kB inhibitors | NFKBIA, IKBKB, IKBKG | CYP2C19 2526/4885NPC1 3842/4885RAB9A 4479/4885 |
| US-20040167155-A1 | Substituted dihydrophenanthridinesulfonamides | TNNT2, TNNI3, SIRT5 | CYP2C19 2958/4885NPC1 3397/4885RAB9A 1423/4885 |
| US-20060160836-A1 | Estrogen receptor structure | ESR2, ESR1, ESRRG | CYP2C19 1579/4885NPC1 3510/4885RAB9A 3807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.